Cell transplantation for the treatment of phase 2 neovascular AMD, in which RPE cells are degenerated but the photoreceptors are functional, will require genetically modified, autologous, PEDF and/or endostatin-transfected pigment epithelial cells transplanted as a monolayer on a biocompatible substratum that supports RPE cell functions. The gene discussed is COL18A1; the disease is age-related macular degeneration.